Dapagliflozin (Forxiga®)

DRUG3 trials

Sponsors

University Hospital Tuebingen, University Medical Center Groningen

Conditions

PreDiabetesRenal FailureType 1 Diabetes Mellitus With Diabetic NephropathyType 2 Diabetes Mellitus (T2DM)Type2diabetes

Phase 2

dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation

Not yet recruitingNCT06072326

University Medical Center GroningenType 1 Diabetes Mellitus With Diabetic Nephropathy

Start: 2026-01-31End: 2028-12-31Target: 36Updated: 2025-10-07

Phase 4

Dapagliflozin Effect on Erythropoiesis and Physical Fitness

WithdrawnNCT03423355

University Hospital TuebingenType 2 Diabetes Mellitus (T2DM)

Start: 2021-09-30End: 2023-12-31Updated: 2021-12-15

SGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes

RecruitingNCT06054035

University Hospital TuebingenPreDiabetes, Renal Failure, Type2diabetes

Start: 2023-10-26End: 2027-09-30Target: 170Updated: 2026-09-15